AR110055A2 - Modulación de receptores quimiosensoriales y ligandos relacionados con los mismos - Google Patents
Modulación de receptores quimiosensoriales y ligandos relacionados con los mismosInfo
- Publication number
- AR110055A2 AR110055A2 ARP170103140A ARP170103140A AR110055A2 AR 110055 A2 AR110055 A2 AR 110055A2 AR P170103140 A ARP170103140 A AR P170103140A AR P170103140 A ARP170103140 A AR P170103140A AR 110055 A2 AR110055 A2 AR 110055A2
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- alkyl
- heteroalkyl
- arylalkyl
- acyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/20—Protein or domain folding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/30—Detection of binding sites or motifs
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/50—Mutagenesis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Theoretical Computer Science (AREA)
- Medical Informatics (AREA)
- Evolutionary Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
Abstract
Reivindicación 1: Un compuesto, excluyendo su uso terapéutico, que tiene la fórmula estructural (1), o un tautómero o sal del mismo, en donde: A es alquilo, alquilo sustituido, halo, -CN, -NO₂, -OR⁹, SR⁹, -NHOR⁹, -NR⁹R¹⁰ o -NOR⁹; B es -N- o -C(R¹²)-; (D)ₙ-G es un resto de fórmula (2) ó (3); E es -NR¹⁷, -N- o -C(R¹⁸)-; H es -C(R³⁵)- o -N-; I es -C(R³⁶) o -N-; J es -C(R³⁷)- o -N-; K es -C(R³⁸)- o -N-; R⁹, R¹⁰, R¹³, R¹⁴ y R¹⁸ son independientemente hidrógeno, alquilo, alquilo sustituido, arilo, arilo sustituido, arilalquilo, arilalquilo sustituido, acilo, acilo sustituido, heteroalquilo, heteroalquilo sustituido, heteroarilo, heteroarilo sustituido, heteroarilalquilo o heteroarilalquilo sustituido; o alternativamente, R⁹ y R¹⁰ o R¹³ y R¹⁴, junto con los átomos a los cuales están unidos, forman un anillo cicloheteroalquilo o cicloheteroalquilo sustituido; R¹² es hidrógeno, alquilo, alquilo sustituido, arilo, arilo sustituido, arilalquilo, arilalquilo sustituido, acilo, acilo sustituido, heteroalquilo, heteroalquilo sustituido, heteroarilo, heteroarilo sustituido, heteroarilalquilo, heteroarilalquilo sustituido, -NR¹³R¹⁴, CN, -OR¹³, -CO₂R¹³ o -CONR¹³R¹⁴; R¹⁷ es hidrógeno, alquilo, alquilo sustituido, arilo, arilo sustituido, arilalquilo, arilalquilo sustituido, acilo, acilo sustituido, heteroalquilo, heteroalquilo sustituido, heteroarilo, heteroarilo sustituido, heteroarilalquilo o heteroarilalquilo sustituido; R³⁵ es hidrógeno, alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, arilo, arilo sustituido, arilalquilo, arilalquilo sustituido, acilo, acilo sustituido, halo, cicloalquenilo, cicloalquenilo sustituido, heteroalquilo, heteroalquilo sustituido, heteroarilo, heteroarilo sustituido, heteroarilalquilo, heteroarilalquilo sustituido, -CN, -NO₂, -OR³⁹, -NR³⁹R⁴⁰, -CONR³⁹R⁴⁰ o -CO₂R³⁹; R³⁶ es hidrógeno, alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, arilo, arilo sustituido, arilalquilo, arilalquilo sustituido, acilo, acilo sustituido, halo, cicloalquenilo, cicloalquenilo sustituido, heteroalquilo, heteroalquilo sustituido, heteroarilo, heteroarilo sustituido, heteroarilalquilo, heteroarilalquilo sustituido, -CN, -NO₂, -OR⁴¹, NR⁴¹R⁴², -CONR⁴¹R⁴² o -CO₂R⁴¹; R³⁷ es hidrógeno, alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, arilo, arilo sustituido, arilalquilo, arilalquilo sustituido, acilo, acilo sustituido, halo, cicloalquenilo, cicloalquenilo sustituido, heteroalquilo, heteroalquilo sustituido, heteroarilo, heteroarilo sustituido, heteroarilalquilo, heteroarilalquilo sustituido, -CN, -NO₂, -OR⁴³, -NR⁴³R⁴⁴, -CONR⁴³R⁴⁴ o -CO₂R⁴³; R³⁸ es hidrógeno, alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, arilo, arilo sustituido, arilalquilo, arilalquilo sustituido, acilo, acilo sustituido, halo, cicloalquenilo, cicloalquenilo sustituido, heteroalquilo, heteroalquilo sustituido, heteroarilo, heteroarilo sustituido, heteroarilalquilo, heteroarilalquilo sustituido, -CN, -NO₂, -OR⁴⁵, -NR⁴⁵R⁴⁶, -CONR⁴⁵R⁴⁶, -COR⁴⁵ o -CO₂R⁴⁵; o alternativamente R³⁶ y R³⁷ o R³⁷ y R³⁸, tomados junto con el átomo al cual están unidos, forman un anillo cicloalquilo, cicloalquilo sustituido, cicloheteroalquilo, o cicloheteroalquilo sustituido; R³⁹, R⁴⁰, R⁴¹, R⁴², R⁴³, R⁴⁴, R⁴⁵ y R⁴⁶ son independientemente hidrógeno, alquilo, alquilo sustituido, arilo, arilo sustituido, arilalquilo, arilalquilo sustituido, acilo, acilo sustituido, heteroalquilo, heteroalquilo sustituido, heteroarilo, heteroarilo sustituido, heteroarilalquilo o heteroarilalquilo sustituido, o alternativamente R³⁹ y R⁴⁰, R⁴¹ y R⁴², R⁴³ y R⁴⁴ o R⁴⁵ y R⁴⁶, junto con los átomos a los cuales están unidos, forman un anillo cicloheteroalquilo o cicloheteroalquilo sustituido; con la condición de que, como máximo, dos de H, I, J y K sean -N-.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/760,592 US9603848B2 (en) | 2007-06-08 | 2007-06-08 | Modulation of chemosensory receptors and ligands associated therewith |
Publications (1)
Publication Number | Publication Date |
---|---|
AR110055A2 true AR110055A2 (es) | 2019-02-20 |
Family
ID=40096447
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP170103138A AR110053A2 (es) | 2007-06-08 | 2017-11-10 | Modulación de receptores quimiosensoriales y ligandos relacionados con los mismos |
ARP170103141A AR110056A2 (es) | 2007-06-08 | 2017-11-10 | Modulación de receptores quimiosensoriales y ligandos relacionados con los mismos |
ARP170103139A AR110054A2 (es) | 2007-06-08 | 2017-11-10 | Modulación de receptores quimiosensoriales y ligandos relacionados con los mismos |
ARP170103140A AR110055A2 (es) | 2007-06-08 | 2017-11-10 | Modulación de receptores quimiosensoriales y ligandos relacionados con los mismos |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP170103138A AR110053A2 (es) | 2007-06-08 | 2017-11-10 | Modulación de receptores quimiosensoriales y ligandos relacionados con los mismos |
ARP170103141A AR110056A2 (es) | 2007-06-08 | 2017-11-10 | Modulación de receptores quimiosensoriales y ligandos relacionados con los mismos |
ARP170103139A AR110054A2 (es) | 2007-06-08 | 2017-11-10 | Modulación de receptores quimiosensoriales y ligandos relacionados con los mismos |
Country Status (2)
Country | Link |
---|---|
US (1) | US9603848B2 (es) |
AR (4) | AR110053A2 (es) |
Families Citing this family (108)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1831225A2 (en) | 2004-11-19 | 2007-09-12 | The Regents of the University of California | Anti-inflammatory pyrazolopyrimidines |
KR20090017498A (ko) | 2006-04-04 | 2009-02-18 | 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 | Pi3 키나제 길항물질 |
US7928111B2 (en) * | 2007-06-08 | 2011-04-19 | Senomyx, Inc. | Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors |
US8633186B2 (en) | 2007-06-08 | 2014-01-21 | Senomyx Inc. | Modulation of chemosensory receptors and ligands associated therewith |
GB2467670B (en) | 2007-10-04 | 2012-08-01 | Intellikine Inc | Chemical entities and therapeutic uses thereof |
CN101965336B (zh) | 2008-01-04 | 2015-06-17 | 英特利凯恩有限责任公司 | 某些化学实体、组合物和方法 |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
EP2252293B1 (en) | 2008-03-14 | 2018-06-27 | Intellikine, LLC | Kinase inhibitors and methods of use |
CA2726588C (en) | 2008-06-03 | 2019-04-16 | Karl Kossen | Compounds and methods for treating inflammatory and fibrotic disorders |
US20110224223A1 (en) | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
CA2730106A1 (en) | 2008-07-08 | 2010-01-14 | Intellikine, Inc. | Kinase inhibitors and methods of use |
EP2323997B1 (en) | 2008-07-31 | 2017-09-06 | Senomyx, Inc. | Processes and intermediates for making sweet taste enhancers |
US8609173B2 (en) | 2008-07-31 | 2013-12-17 | Senomyx Inc. | Compositions comprising sweetness enhancers and methods of making them |
CA2738429C (en) | 2008-09-26 | 2016-10-25 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
US20110224250A1 (en) * | 2008-10-09 | 2011-09-15 | Yasushi Kohno | Isoquinoline derivative, and pde inhibitor comprising same as active ingredient |
US8697709B2 (en) | 2008-10-16 | 2014-04-15 | The Regents Of The University Of California | Fused ring heteroaryl kinase inhibitors |
US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
BRPI0921625A2 (pt) | 2008-11-04 | 2016-01-05 | Univ Kentucky Res Foundation Inc | composicoes baseadas em d-tagatose e metodos para previnir e tratar aterosclerose, sindrome metabolica, e sintomas dos mesmos |
WO2010103306A1 (en) * | 2009-03-10 | 2010-09-16 | Astrazeneca Uk Limited | Benzimidazole derivatives and their use as antivaral agents |
CA2758976C (en) | 2009-04-20 | 2015-02-03 | Alain Baron | Chemosensory receptor ligand-based therapies |
US8828953B2 (en) * | 2009-04-20 | 2014-09-09 | NaZura BioHealth, Inc. | Chemosensory receptor ligand-based therapies |
US9901551B2 (en) | 2009-04-20 | 2018-02-27 | Ambra Bioscience Llc | Chemosensory receptor ligand-based therapies |
WO2010129816A2 (en) | 2009-05-07 | 2010-11-11 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
ES2486715T3 (es) | 2009-06-29 | 2014-08-19 | Incyte Corporation | Pirimidinonas como inhibidores de PI3K |
CN102753535B (zh) | 2009-09-03 | 2015-03-25 | 百时美施贵宝公司 | 作为钾离子通道抑制剂的喹唑啉 |
WO2011047384A2 (en) | 2009-10-16 | 2011-04-21 | The Regents Of The University Of California | Methods of inhibiting ire1 |
US8470817B2 (en) * | 2009-10-26 | 2013-06-25 | Sunesis Pharmaceuticals, Inc. | Compounds and methods for treatment of cancer |
TW201130842A (en) * | 2009-12-18 | 2011-09-16 | Incyte Corp | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors |
WO2011075643A1 (en) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted heteroaryl fused derivatives as pi3k inhibitors |
SG184156A1 (en) | 2010-04-02 | 2012-10-30 | Senomyx Inc | Sweet flavor modifier |
AR081823A1 (es) | 2010-04-14 | 2012-10-24 | Incyte Corp | DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd |
JP5951600B2 (ja) | 2010-05-21 | 2016-07-13 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | キナーゼ調節のための、化合物、組成物および方法 |
US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
BR112013003332B1 (pt) * | 2010-08-12 | 2018-11-13 | Senomyx, Inc. | método para melhorar a estabilidade de intensificador de doce e composição contendo intensificador de doce estabilizado |
EA201370099A1 (ru) * | 2010-10-19 | 2013-11-29 | Элселикс Терапьютикс, Инк. | Терапия на основе лигандов хемосенсорных рецепторов |
JP2013545749A (ja) | 2010-11-10 | 2013-12-26 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | 複素環化合物及びその使用 |
TW201249844A (en) | 2010-12-20 | 2012-12-16 | Incyte Corp | N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors |
HUE051738T2 (hu) | 2011-01-07 | 2021-03-29 | Anji Pharma Us Llc | Kemoszenzoros receptorligandum-alapú terápiák |
JP2014501790A (ja) | 2011-01-10 | 2014-01-23 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | イソキノリノンの調製方法及びイソキノリノンの固体形態 |
JP6130305B2 (ja) | 2011-02-23 | 2017-05-17 | インテリカイン, エルエルシー | キナーゼ阻害剤の組み合わせおよびそれらの使用 |
US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
WO2012135009A1 (en) | 2011-03-25 | 2012-10-04 | Incyte Corporation | Pyrimidine-4,6-diamine derivatives as pi3k inhibitors |
EP2734530A1 (en) | 2011-07-19 | 2014-05-28 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CN103930422A (zh) | 2011-07-19 | 2014-07-16 | 无限药品股份有限公司 | 杂环化合物及其用途 |
JP5985640B2 (ja) * | 2011-08-12 | 2016-09-06 | セノミックス インコーポレイテッド | 甘味修飾物質 |
JP6029668B2 (ja) | 2011-08-29 | 2016-11-24 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | 複素環式化合物及びその使用 |
MX370814B (es) | 2011-09-02 | 2020-01-08 | Univ California | Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas. |
ME02595B (me) | 2011-09-02 | 2017-06-20 | Incyte Holdings Corp | Heterociklilamini kao inhibitori pi3k |
EP2758402B9 (en) | 2011-09-22 | 2016-09-14 | Pfizer Inc | Pyrrolopyrimidine and purine derivatives |
ES2661864T3 (es) | 2011-12-22 | 2018-04-04 | Novartis Ag | Derivados de 2,3-dihidro-benzo[1,4]oxazina y compuestos relacionados como inhibidores de fosfoinositida-3 quinasa (PI3K) para el tratamiento de por ejemplo artritis reumatoide |
AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2013158928A2 (en) | 2012-04-18 | 2013-10-24 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
ES2806606T3 (es) | 2012-08-06 | 2021-02-18 | Firmenich Incorporated | Modificador del sabor dulce |
BR112015006828A8 (pt) | 2012-09-26 | 2019-09-17 | Univ California | composto, ou um sal farmaceuticamente aceitável do mesmo; composição farmacêutica; uso do composto; e método para modular a atividade de uma proteína ire1 |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
JO3155B1 (ar) | 2013-02-19 | 2017-09-20 | Senomyx Inc | معدِّل نكهة حلوة |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
US9227985B2 (en) | 2013-03-15 | 2016-01-05 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
US9290514B2 (en) | 2013-07-08 | 2016-03-22 | Incyte Holdings Corporation | Tricyclic heterocycles as BET protein inhibitors |
WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CN105793255B (zh) | 2013-10-04 | 2018-11-16 | 无限药品股份有限公司 | 杂环化合物及其用途 |
CA2926950C (en) | 2013-10-10 | 2022-10-11 | Eastern Virginia Medical School | 4-((2-hydroxy-3-methoxybenzyl)amino) benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase |
US9315501B2 (en) | 2013-11-26 | 2016-04-19 | Incyte Corporation | Bicyclic heterocycles as BET protein inhibitors |
US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
US9309246B2 (en) | 2013-12-19 | 2016-04-12 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
US9775844B2 (en) | 2014-03-19 | 2017-10-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2015153683A1 (en) | 2014-04-02 | 2015-10-08 | Intermune, Inc. | Anti-fibrotic pyridinones |
WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
DK3674302T3 (da) | 2014-04-23 | 2023-04-03 | Incyte Holdings Corp | 1h-pyrrolo[2,3-c]pyridin-7(6h)-oner og pyrazolo[3,4-c]pyridin-7(6h)-oner som inhibitorer af bet-proteiner |
WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
EP3162366A4 (en) | 2014-06-27 | 2018-02-14 | Ajinomoto Co., Inc. | Sweetness receptor antagonist |
ES2855225T3 (es) | 2014-09-15 | 2021-09-23 | Incyte Corp | Heterociclos tricíclicos para su uso como inhibidores de proteínas BET |
WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US11339128B2 (en) | 2014-11-07 | 2022-05-24 | Firmenich Incorporated | Substituted 4-amino-5-(cyclohexyloxy)quinoline-3-carboxylic acids as sweet flavor modifiers |
KR20170132185A (ko) | 2015-02-27 | 2017-12-01 | 인사이트 코포레이션 | Pi3k 억제제의 염 및 이의 제조 공정 |
CU20170115A7 (es) | 2015-03-04 | 2018-03-13 | Gilead Sciences Inc | Compuestos moduladores de receptor de tipo toll |
WO2016183060A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
WO2016183063A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Crystalline forms of a pi3k inhibitor |
CN105232565B (zh) * | 2015-08-13 | 2017-12-08 | 北京农学院 | 罗汉果皂苷或其药学上可接受的盐在制备肿瘤放射增敏剂中的应用 |
CN108349985A (zh) | 2015-09-14 | 2018-07-31 | 无限药品股份有限公司 | 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法 |
TW201722966A (zh) | 2015-10-29 | 2017-07-01 | 英塞特公司 | Bet蛋白質抑制劑之非晶固體形式 |
WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
KR102643344B1 (ko) | 2016-06-20 | 2024-03-07 | 인사이트 코포레이션 | Bet 저해제의 결정질 고체 형태 |
US11147818B2 (en) | 2016-06-24 | 2021-10-19 | Infinity Pharmaceuticals, Inc. | Combination therapies |
EP3507276B1 (en) | 2016-09-02 | 2021-11-03 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
US10640499B2 (en) | 2016-09-02 | 2020-05-05 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
SI3319949T1 (sl) | 2016-09-21 | 2020-11-30 | Celanese International Corporation, | Sestavki kalijevega acesulfama in postopki za njihovo izdelavo |
LT3322695T (lt) | 2016-09-21 | 2020-11-10 | Celanese International Corporation | Kalio acesulfamo kompozicijos ir jų gamybos būdas |
RS62400B1 (sr) | 2016-09-21 | 2021-10-29 | Celanese Int Corp | Kompozicije acesulfam-kalijuma i postupci za njihovu proizvodnju |
WO2018057386A1 (en) | 2016-09-21 | 2018-03-29 | Celanese International Corporation | Acesulfame potassium compositions and processes for producing same |
JP2020523367A (ja) | 2017-06-13 | 2020-08-06 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | H−pgds阻害剤としての化学化合物 |
CN112703193A (zh) | 2018-08-07 | 2021-04-23 | 弗门尼舍公司 | 5-取代的4-氨基-1H-苯并[c][1,2,6]噻二嗪2,2-二氧化物及其制剂和用途 |
TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TW202115056A (zh) | 2019-06-28 | 2021-04-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑化合物的製備方法 |
AR121047A1 (es) | 2020-01-15 | 2022-04-13 | Blueprint Medicines Corp | Inhibidores de map4k1 |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
EP4258895A1 (en) | 2021-01-15 | 2023-10-18 | Firmenich Incorporated | Sweetener compostions comprising siamenoside i and uses thereof |
US20240065302A1 (en) | 2021-01-15 | 2024-02-29 | Firmenich Incorporated | Sweetener compositions comprising mogrosides and uses thereof |
JP2024503101A (ja) | 2021-01-15 | 2024-01-24 | フィルメニッヒ インコーポレイテッド | モグロシドを含む甘味料組成物およびその使用 |
WO2023172415A1 (en) | 2022-03-07 | 2023-09-14 | Firmenich Incorporated | Sweetener compositions |
WO2023169995A1 (en) | 2022-03-10 | 2023-09-14 | Firmenich Sa | Sweetener compositions |
WO2023198436A2 (en) | 2022-04-11 | 2023-10-19 | Firmenich Sa | Sweetener compositions |
NL2033363B1 (en) | 2022-10-20 | 2024-05-08 | Univ Eindhoven Tech | A non-aqueous redox flow battery |
Family Cites Families (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB951651A (en) | 1960-02-17 | 1964-03-11 | Shell Res Ltd | Substituted benzonitriles, their preparation and compositions containing them |
US3278532A (en) | 1964-07-06 | 1966-10-11 | Sandoz Ag | Dioxybenzothiadiazines |
US3857972A (en) | 1971-03-10 | 1974-12-31 | Int Flavors & Fragrances Inc | Flavoring with an oxocyclic pyrimidine |
US3843804A (en) | 1971-03-10 | 1974-10-22 | Int Flavors & Fragrances Inc | Novel flavoring compositions and processes |
LU64388A1 (es) | 1971-12-02 | 1973-07-16 | ||
FI54312C (fi) | 1972-05-09 | 1978-11-10 | Sumitomo Chemical Co | Foerfarande foer framstaellning av tieno-(2,3-d)pyrimidinderivat med avsoendring av urinsyra i urin utoekande |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3960860A (en) | 1973-01-08 | 1976-06-01 | International Flavors & Fragrances Inc. | 2-Methyl-5,7-dihydrothieno-[3,4d]-pyrimidine |
US4036837A (en) | 1973-03-23 | 1977-07-19 | American Home Products Corporation | 2 Alkoxyoxamoyl-pyrazines |
US3966965A (en) | 1973-03-23 | 1976-06-29 | American Home Products Corporation | Oxamic acid derivatives for the prevention of immediate type hypersensitivity reactions |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US3960783A (en) * | 1974-04-01 | 1976-06-01 | Ciba-Geigy Corporation | Novel polymers from s-triazine cyanamide compounds |
GB1570494A (en) | 1975-11-28 | 1980-07-02 | Ici Ltd | Thienopyrimidine derivatives and their use as pesticides |
US4137325A (en) | 1977-03-17 | 1979-01-30 | American Home Products Corporation | Antisecretory oxamic acid esters |
US4196207A (en) | 1977-05-23 | 1980-04-01 | Ici Australia Limited | Process for controlling eradicating or preventing infestations of animals by Ixodid ticks |
ES472163A1 (es) | 1978-07-28 | 1979-03-16 | Consejo Superior Investigacion | Ÿun nuevo procedimiento para la obtencion de 5,5-dioxido de 7-amino-2h-4h-vic-triazolo (4,5-c) (1,2,6) tiadiazinaÿ |
IE51802B1 (en) | 1979-12-03 | 1987-04-01 | Fujisawa Pharmaceutical Co | Quinazoline derivatives,processes for their preparation and pharmaceutical compositions containing them |
JPS5951290A (ja) | 1982-09-14 | 1984-03-24 | Dai Ichi Seiyaku Co Ltd | ベンゾチエノイミダゾピリミジンジオン化合物 |
ES531159A0 (es) | 1984-03-30 | 1985-09-01 | Consejo Superior Investigacion | Procedimiento para la preparacion de aminociclotiadiazinas |
GB8504253D0 (en) | 1985-02-19 | 1985-03-20 | Ici Plc | Electrostatic spraying apparatus |
US4672116A (en) | 1985-12-20 | 1987-06-09 | Ortho Pharmaceutical Corporation | Substituted 5,6-dialkoxyquinazoline derivatives |
JPS6387959A (ja) | 1986-10-01 | 1988-04-19 | Sanyo Kokusaku Pulp Co Ltd | ステビア甘味料の呈味性改善法 |
US4960870A (en) | 1987-02-11 | 1990-10-02 | Ciba-Geigy Corporation | Heavy metal complex azo dyes containing a benzothiophene-1,1-dioxide, 2,1-benzothiazine-2,2-dioxide, 1,4-benzothiazine-1,1-dioxide or thienopyridine-1,1-dioxide coupling component |
AU617121B2 (en) | 1987-07-17 | 1991-11-21 | Nutrasweet Company, The | Substituted guanidines containing a tetrazolyl moiety and their use as high potency sweetening agents |
US5380541A (en) | 1987-08-07 | 1995-01-10 | Tate & Lyle Public Limited Company | Sucralose compositions |
DE3815221C2 (de) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen |
JPH02238856A (ja) | 1989-03-14 | 1990-09-21 | Mitajiri Kagaku Kogyo Kk | ミラクリンを有効成分とする矯味・調味料及びこれを含有する飲食品 |
US5192785A (en) | 1989-09-03 | 1993-03-09 | A. H. Robins Company, Incorporated | Sulfamates as antiglaucoma agents |
US5504095A (en) | 1990-09-19 | 1996-04-02 | Pfizer Inc. | Aminobenzosultam derivatives as lipoxygenase inhibitors |
US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
IL102764A0 (en) | 1991-08-16 | 1993-01-31 | Merck & Co Inc | Quinazoline derivatives,and pharmaceutical compositions containing them |
PT100905A (pt) | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
GB9127188D0 (en) | 1991-12-21 | 1992-02-19 | Smithkline Beecham Plc | Novel compounds |
KR970010069B1 (ko) | 1992-08-24 | 1997-06-20 | 주식회사 럭키 | 신규 세팔로스포린계 항생제 및 이의 제조방법 |
CA2215248A1 (en) | 1995-03-14 | 1996-09-19 | Siemens Aktiengesellschaft | Ultrasonic atomizer device with removable precision dosing unit |
AU690438B2 (en) | 1995-03-14 | 1998-04-23 | Siemens Aktiengesellschaft | Ultrasonic atomizer device with removable precision dosating unit |
US6046206A (en) | 1995-06-07 | 2000-04-04 | Cell Pathways, Inc. | Method of treating a patient having a precancerous lesions with amide quinazoline derivatives |
DE19632423A1 (de) | 1996-08-12 | 1998-02-19 | Merck Patent Gmbh | Thienopyrimidine |
CA2273241A1 (en) | 1996-12-20 | 1998-07-02 | Nutrinova Nutrition Special Ties & Food Ingredients Gmbh | Method for increasing the sweetening power and enhancing the taste of a mixture of extremely powerful sweetening agents |
KR100220953B1 (ko) | 1996-12-31 | 1999-10-01 | 김영환 | 아미드 또는 이미드를 도입한 ArF 감광막 수지 |
GB9711650D0 (en) | 1997-06-05 | 1997-07-30 | Pfizer Ltd | Compounds useful in therapy |
US5954047A (en) | 1997-10-17 | 1999-09-21 | Systemic Pulmonary Development, Ltd. | Methods and apparatus for delivering aerosolized medication |
US5990117A (en) | 1998-04-15 | 1999-11-23 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives |
HUP0102793A3 (en) | 1998-05-28 | 2002-07-29 | Parker Hughes Inst St Paul | Quinazolines for treating brain tumor and medicaments containing them |
US6169118B1 (en) | 1998-11-12 | 2001-01-02 | Block Drug Company, Inc. | Flavor blend for masking unpleasant taste of zinc compounds |
JP2003500397A (ja) | 1999-05-19 | 2003-01-07 | スミスクライン ビーチャム パブリック リミテッド カンパニー | Mrs阻害剤としての2−nh−ピリドンおよびピリミドン |
GB9915995D0 (en) | 1999-07-09 | 1999-09-08 | Ahmed S | Non-steroidal sulphamate compounds for use as oestrone sulphatase inhibitors |
JP3523166B2 (ja) | 1999-09-02 | 2004-04-26 | 高砂香料工業株式会社 | 食品香料劣化防止剤、食品香料劣化防止方法およびその食品香料劣化防止剤を含有する食品 |
TW201006846A (en) | 2000-03-07 | 2010-02-16 | Senomyx Inc | T1R taste receptor and genes encidung same |
MXPA02009843A (es) | 2000-04-07 | 2004-09-06 | Senomyx Inc | Receptores t2r del sabor y genes que codifican para los mismos. |
TW201022287A (en) | 2001-01-03 | 2010-06-16 | Senomyx Inc | T1R taste receptors and genes encoding same |
AU2002233708B2 (en) | 2001-03-02 | 2007-02-08 | Nissan Chemical Industries, Ltd. | Process for producing quinoline-3-carboxylic acid compound |
US7368285B2 (en) | 2001-03-07 | 2008-05-06 | Senomyx, Inc. | Heteromeric umami T1R1/T1R3 taste receptors and isolated cells that express same |
EP2003451B1 (en) | 2001-06-26 | 2012-05-30 | Senomyx, Inc. | T1r1-t1r3 hetero-oligomeric umami taste receptors and cell lines that express said receptors and use thereof for identification of umami taste compounds |
AU2002320294B2 (en) | 2001-07-03 | 2009-01-15 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Mammalian sweet and amino acid heterodimeric taste receptors |
US20060134693A1 (en) | 2001-07-06 | 2006-06-22 | Guy Servant | Olfactory cyclic nucleotide-gated channel cell-based assays to identify T1R and T2R taste modulators |
EP1415545B1 (en) | 2001-07-19 | 2006-01-25 | San-Ei Gen F.F.I., Inc. | Flavor-improving compositions and application thereof |
AU2002336462A1 (en) | 2001-09-06 | 2003-03-24 | Millennium Pharmaceuticals, Inc. | Piperazine and homopiperazine compounds |
ATE343577T1 (de) | 2001-12-14 | 2006-11-15 | Merck Frosst Canada Ltd | Quinolinone als prostaglandin rezeptor liganden |
WO2003055866A1 (en) | 2001-12-21 | 2003-07-10 | Bayer Pharmaceuticals Corporation | Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
GB0206033D0 (en) | 2002-03-14 | 2002-04-24 | Pfizer Ltd | Compounds useful in therapy |
WO2004012746A2 (en) | 2002-08-02 | 2004-02-12 | The Regents Of The University Of California | New uses for inhibitors of inosine monophosphate dehydrogenase |
GB0230015D0 (en) | 2002-12-23 | 2003-01-29 | Novartis Ag | Organic compounds |
DE10324548A1 (de) | 2003-05-28 | 2004-12-16 | Nutrinova Nutrition Specialties & Food Ingredients Gmbh | Diätisches Lebensmittel bei einer gewichtskontrollierenden bzw. gewichtsreduzierenden Ernährung |
ES2733577T3 (es) | 2003-08-06 | 2019-12-02 | Senomyx Inc | Nuevos aromas, modificadores del aroma, saborizantes, intensificadores del sabor, saborizantes umami o dulces y/o intensificadores y uso de los mismos |
WO2005016889A1 (en) | 2003-08-08 | 2005-02-24 | Virginia Commonwealth University | Compounds having antiestrogenic and tissue selective estrogenic properties |
US20050196503A1 (en) | 2004-03-05 | 2005-09-08 | Sunil Srivastava | High-intensity sweetener-polyol compositions |
EP1753864A2 (en) | 2004-04-14 | 2007-02-21 | Monell Chemical Senses Center | Taste receptors of the t1r family from domestic dog |
JP5001150B2 (ja) | 2004-06-08 | 2012-08-15 | ファミリーズ オブ スパイナル マスキュラー アトロフィー | 脊髄性筋萎縮症のための2,4−ジアミノキナゾリン |
US20060045953A1 (en) | 2004-08-06 | 2006-03-02 | Catherine Tachdjian | Aromatic amides and ureas and their uses as sweet and/or umami flavor modifiers, tastants and taste enhancers |
CN101035442B (zh) | 2004-10-15 | 2012-04-11 | 味之素株式会社 | 甜味剂组合物 |
US20080261823A1 (en) | 2004-12-10 | 2008-10-23 | Yitzhak Tor | Fluorescent Nucleoside Analogs That Mimic Naturally Occurring Nucleosides |
PL1828199T3 (pl) | 2004-12-17 | 2009-10-30 | Hoffmann La Roche | Pochodne tieno-pirydyny jako alosteryczne wzmacniacze gaba-b |
CA2597134C (en) | 2005-02-04 | 2015-05-26 | Senomyx, Inc. | Compounds comprising linked heteroaryl moieties and their use as novel umami flavor modifiers, tastants and taste enhancers for comestible compositions |
WO2006084184A2 (en) | 2005-02-04 | 2006-08-10 | Senomyx, Inc. | Molecules comprising linked organic moieties as flavor modifiers for comestible compositions |
US8796441B2 (en) | 2005-04-13 | 2014-08-05 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Human sweet and umami taste receptor variants |
WO2006113432A2 (en) | 2005-04-14 | 2006-10-26 | Smithkline Beecham Corporation | Compounds, compositions and methods |
AR055329A1 (es) | 2005-06-15 | 2007-08-15 | Senomyx Inc | Amidas bis-aromaticas y sus usos como modificadores de sabor dulce, saborizantes, y realzadores de sabor |
JP2007007591A (ja) | 2005-07-01 | 2007-01-18 | Mikuni Corp | 電解水及びその製造方法 |
US7915410B2 (en) | 2005-09-09 | 2011-03-29 | Bristol-Myers Squibb Company | Acyclic IKur inhibitors |
AU2006304797B2 (en) | 2005-10-20 | 2013-01-31 | Senomyx, Inc. | Chimeric human sweet-umami and umami-sweet taste receptors |
US8506956B2 (en) | 2005-10-31 | 2013-08-13 | Kaneka Corporation | Method for stabilizing reduced coenzyme Q10 |
CA2632929A1 (en) | 2005-12-22 | 2007-06-28 | Astrazeneca Ab | Quinazoline derivatives, process for their preparation and their use as anti-cancer agents |
US20090286863A1 (en) | 2006-07-05 | 2009-11-19 | David Bruge | Sulfamatobenzothiophene derivatives |
RU2009101298A (ru) | 2006-08-22 | 2010-09-27 | Рэдпойнт Био Корпорэйшн (Us) | Гетероциклические соединения в качестве усилителей подслащивающего вещества |
US7928111B2 (en) | 2007-06-08 | 2011-04-19 | Senomyx, Inc. | Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors |
US8633186B2 (en) | 2007-06-08 | 2014-01-21 | Senomyx Inc. | Modulation of chemosensory receptors and ligands associated therewith |
WO2009006722A1 (en) | 2007-07-12 | 2009-01-15 | Mehrzad Gomari | Paper-free local flyer advertising (a technology method of localized internet advertising) |
US8609173B2 (en) | 2008-07-31 | 2013-12-17 | Senomyx Inc. | Compositions comprising sweetness enhancers and methods of making them |
EP2323997B1 (en) * | 2008-07-31 | 2017-09-06 | Senomyx, Inc. | Processes and intermediates for making sweet taste enhancers |
SG184156A1 (en) | 2010-04-02 | 2012-10-30 | Senomyx Inc | Sweet flavor modifier |
EP2587939B1 (en) | 2010-06-29 | 2014-03-19 | Firmenich SA | Active ingredient delivery system |
BR112013003332B1 (pt) | 2010-08-12 | 2018-11-13 | Senomyx, Inc. | método para melhorar a estabilidade de intensificador de doce e composição contendo intensificador de doce estabilizado |
US20130338095A1 (en) | 2010-10-19 | 2013-12-19 | Elcelyx Therapeutics, Inc. | Chemosensory Receptor Ligand-Based Therapies |
ES2806606T3 (es) * | 2012-08-06 | 2021-02-18 | Firmenich Incorporated | Modificador del sabor dulce |
JO3155B1 (ar) | 2013-02-19 | 2017-09-20 | Senomyx Inc | معدِّل نكهة حلوة |
-
2007
- 2007-06-08 US US11/760,592 patent/US9603848B2/en active Active
-
2017
- 2017-11-10 AR ARP170103138A patent/AR110053A2/es unknown
- 2017-11-10 AR ARP170103141A patent/AR110056A2/es unknown
- 2017-11-10 AR ARP170103139A patent/AR110054A2/es unknown
- 2017-11-10 AR ARP170103140A patent/AR110055A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20080306093A1 (en) | 2008-12-11 |
AR110056A2 (es) | 2019-02-20 |
US9603848B2 (en) | 2017-03-28 |
AR110053A2 (es) | 2019-02-20 |
AR110054A2 (es) | 2019-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR110055A2 (es) | Modulación de receptores quimiosensoriales y ligandos relacionados con los mismos | |
AR098912A1 (es) | Inhibidores de syk | |
AR107616A1 (es) | Compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos | |
AR089807A1 (es) | Compuestos de imidazopirrolidinona | |
DOP2015000239A (es) | Derivados de 1-acil-4-amino-1,2,3,4-tetrahidroquinolina 2,3-disustituidos y su uso como inhibidores del bromodominio | |
AR082886A1 (es) | Compuestos y composiciones farmaceuticas que los contienen | |
CY1124537T1 (el) | Παραγωγο πυριδονης που εχει τετραϋδροπυρανυλ μεθυλ ομαδα | |
AR091424A1 (es) | Compuestos triciclicos sustituidos como inhibidores de receptores del factor de crecimiento del fibroplasto (fgfr) | |
MA39189A1 (fr) | Dérivés de 1h-indazole et de 1h-indole antibactériens | |
CO6561817A2 (es) | Derivados de piridina di-sustituida como agentes anticancer | |
AR092838A1 (es) | COMPUESTOS TIPO PIRROLO-PIRROLIDINONA COMO INHIBIDORES DE LA INTERACCION ENTRE p53 Y MDM2 Y/O MDM4 | |
BRPI1011683B8 (pt) | derivados de isoquinolina substituída, suas composições farmacêuticas e seus usos | |
MA38583A1 (fr) | Dérivés de dolastatine 10 et d'auristatines | |
AR067613A1 (es) | Inhibidores de adn-pk, uso y sintesis de los mismos | |
AR079250A1 (es) | Derivados de pirazolo[1,5-a]piridina utiles en el tratamiento de enfermedades del snc y canceres, composiciones farmaceuticas que los contienen e intermediario de sintesis. | |
CU23921B1 (es) | Nuevos derivados dihidroindolonas | |
AR106961A1 (es) | Amidas de ácido malónico sustituidas como insecticida | |
MA38645B1 (fr) | Nouveaux inhibiteurs de cyp17/antiandrogènes | |
CO6480974A2 (es) | Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida, su preparación y su utilización farmacéutica como inhibidores de fosforilación de akt(pkb) | |
CY1117560T1 (el) | Νεο υποκατασταθεν παραγωγο ισοκινολινης | |
AR099690A1 (es) | Ureas asimétricas p-sustituidas como moduladoras de la actividad de ghrelina | |
AR043487A1 (es) | Heterociclos fusionados de pirimidina y usos de los mismos | |
MA20150280A2 (fr) | Dérivés d'aryléthynyle | |
MA38010A1 (fr) | Dérivés d'éthynyl utilisés en tant que modulateurs de l'activité des récepteurs mglur5 | |
BR112014004267A2 (pt) | derivado de ácido pirrolidina-3-ilacético |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |